Aims: To describe #obesity treatments in real-world settings after discontinuation of #semaglutide or #tirzepatide and variability in weight change post-discontinuation.Materials and methods: This retrospective cohort study used electronic health records from 1 January 2021, to 30 June 2025, in a large health system in Ohio and Florida. Adults with overweight or obesity who initiated injectable… Continue reading Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide
2 Medical News 